Retrospective registry of patients with locally advanced/metastatic HR⁺/HER2^- breast cancer treated in clinical practice in Andalusia.

ABSTRACT:

Background

Limited data are available regarding the real-world effectiveness and safety of Cyclin Dependent Kinase 4/6 inhibitor (CDK4/6i) (palbociclib/ribociclib) just as a first-line treatment for patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR + /HER2‒) metastatic breast cancer (MBC).

Objective

To assess whether clinical or demographic characteristics limit access to first-line CDK4/6i treatment in clinical practice in the Autonomous Community of Andalusia (Spain) between November 2017 and April 2020. In addition, effectiveness will be described in an exploratory analysis.

Methods

Physicians from 12 centers participated in selecting demographic and clinical characteristics, treatment, and outcome data from women with HR

SUBMITTER: Chavarria Piudo N 

PROVIDER: S-EPMC11564311 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature